Prescription drug · NDA AUTHORIZED GENERIC
Verapamil Hydrochloride NDC 52536-882
Verapamil hydrochloride 180 mg/1 · Capsule, Delayed release · Oral · Wilshire Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 52536-882-01 | 52536088201 | 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE, PLASTIC (52536-882-01)Marketed from Nov 26, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Verapamil Hydrochloride
- Generic name (nonproprietary)
- verapamil hydrochloride
- Active ingredients
- Verapamil hydrochloride — 180 mg/1
- Dosage form
- Capsule, Delayed release
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 019614
- Marketing start
- Listing expires
- Other FDA classes
- Calcium Channel Antagonists (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
- Identifiers
- Product ID 52536-882_27eb9340-eaec-754a-e063-6394a90a4f6eSPL ID 27eb9340-eaec-754a-e063-6394a90a4f6eSPL set ID f9399858-fd7a-4b73-8759-3e5bf3af2666UNII V3888OEY5RUPC 0352536886017, 0352536882019
- Pharmacologic class
- Calcium Channel Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N452536088201followed by a unit qualifier and the quantityPackage 52536-0882-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 019614
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Verapamil Hydrochloride | Verapamil hydrochloride 120 mg/1 | Capsule, Delayed releaseOral | Wilshire Pharmaceuticals, Inc. | 52536-880 |
| Verapamil Hydrochloride | Verapamil hydrochloride 240 mg/1 | Capsule, Delayed releaseOral | Wilshire Pharmaceuticals, Inc. | 52536-884 |
| Verapamil Hydrochloride | Verapamil hydrochloride 360 mg/1 | Capsule, Delayed releaseOral | Wilshire Pharmaceuticals, Inc. | 52536-886 |
| Verapamil Hydrochloride | Verapamil hydrochloride 120 mg/1 | Capsule, Delayed release pelletsOral | Teva Pharmaceuticals Inc | 0591-2880 |